Hangzhou Sciwind Biosciences Co., Ltd.
Clinical trials sponsored by Hangzhou Sciwind Biosciences Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill could help shed pounds without needles Results expected Jan 2027 (estimated)
- New obesity drug XW003 takes on semaglutide in Head-to-Head trial Results expected Feb 2027 (estimated)
-
New pill could help shed pounds without needles
Disease control Recruiting nowThis study tests an experimental oral drug called ecnoglutide in 84 Chinese adults who are overweight or obese. The main goal is to check safety and how the body processes the drug, while also measuring weight changes. Participants take either the drug or a placebo daily for seve…
Phase 1/2 • Sponsor: Hangzhou Sciwind Biosciences Co., Ltd. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New shot could help sleep apnea patients breathe easier and shed pounds
Disease control Recruiting nowThis study tests an injection called XW003 in 140 obese adults with obstructive sleep apnea who already use a breathing machine (PAP). The goal is to see if the drug reduces breathing pauses during sleep and helps with weight loss. Participants will receive either the drug or a p…
Phase 3 • Sponsor: Hangzhou Sciwind Biosciences Co., Ltd. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New injection could help sleep apnea without CPAP
Disease control Recruiting nowThis phase 3 trial tests an injectable drug called XW003 (Ecnoglutide) in 140 obese adults with obstructive sleep apnea who do not use CPAP machines. The goal is to see if the drug reduces breathing pauses during sleep and helps with weight loss. Participants receive either the d…
Phase 3 • Sponsor: Hangzhou Sciwind Biosciences Co., Ltd. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Weight-loss drug ecnoglutide takes aim at knee osteoarthritis pain
Symptom relief Recruiting nowThis phase 3 trial tests whether ecnoglutide, a GLP-1 drug similar to semaglutide, can reduce knee pain and body weight in obese adults with knee osteoarthritis. Participants receive either ecnoglutide injections or a placebo for several months. The study measures changes in pain…
Phase 3 • Sponsor: Hangzhou Sciwind Biosciences Co., Ltd. • Aim: Symptom relief
Last updated Sep 02, 2026 00:00 UTC